Preparation and in vitro/in vivo evaluation of azilsartan osmotic pump tablets based on the preformulation investigation

References

• Lam S. Azilsartan: a newly approved angiotensin II receptor blocker. Cardiol Rev. 2011;19:300–304.
   PubMed Web of Science ®Google Scholar
• Ojima M, Igata H, Tanaka M, et al. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011;336:801–808.
   PubMed Web of Science ®Google Scholar
• Perez A, Cao C. Azilsartan in patients with mild to moderate hypertension using clinic and ambulatory blood pressure measurements. J Clin Hypertens. 2017;19:82–89.
   Web of Science ®Google Scholar
• Rakugi H, Enya K, Sugiura K, et al. Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Hypertens Res. 2012;35:552–558.
   PubMed Web of Science ®Google Scholar
• Cheng G, Wang JF, Sun YH, et al. UPLC-MS/MS for the determination of azilsartan in beagle dog plasma and its application in a pharmacokinetics study. Asian J Pharm Sci. 2015;10:247–253.
   Web of Science ®Google Scholar
• Zhang X, Yi Y, Qi J, et al. Controlled release of cyclosporine a self-nanoemulsifying systems from osmotic pump tablets: near zero-order release and pharmacokinetics in dogs . Int J Pharm. 2013;452:233–240.
   PubMed Web of Science ®Google Scholar
• Pan H, Jin H, Yang X, et al. Synchronized and controlled release of metformin hydrochloride/glipizide from elementary osmotic delivery. Drug Dev Ind Pharm. 2017;43:780–788.
   PubMed Web of Science ®Google Scholar
• Li ZC, Gai X, Wen H, et al. Aqueous polymer dispersion coating used for osmotic pump tablets: membrane property investigation and IVIVC evaluation. AAPS PharmSciTech. 2017;19:242–250.
   PubMed Web of Science ®Google Scholar
• Cheng L, Li T, Dong L, et al. Design and evaluation of bilayer pump tablet of flurbiprofen solid dispersion for zero-order controlled delivery. J Pharm Sci. 2018;107:1434–1442.
   PubMed Web of Science ®Google Scholar
• Missaghi S, Patel P, Farrell TP, et al. Investigation of critical core formulation and process parameters for osmotic pump oral drug delivery. AAPS PharmSciTech. 2014;15:149–160.
   PubMed Web of Science ®Google Scholar
• Theeuwes F. Elementary osmotic pump. J Pharm Sci. 1975;64:1987–1991.
   PubMed Web of Science ®Google Scholar
• Jiang D, Zeng J, Zhu Y, et al. Sustained-release of cyclosporin a pellets: preparation, in vitro release, pharmacokinetic studies and in vitro-in vivo correlation in beagle dogs. Drug Dev Ind Pharm. 2016;42:1174–1182.
   PubMed Web of Science ®Google Scholar
• Gong W, Liu Y, Mei DY, et al. Preparation, release and pharmacokinetics of a risperidone elementary osmotic pump system. Drug Dev Ind Pharm. 2015;41:464–469.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang M, Li P, et al. Application of hot-melt extrusion technology for designing an elementary osmotic pump system combined with solid dispersion for a novel poorly water-soluble antidepressant. Pharm Dev Technol. 2016;21:1006–1014.
   PubMed Web of Science ®Google Scholar
• Ketjinda W, Sinchaipanid N, Limsuwan P, et al. Development of push-pull osmotic tablets using chitosan-poly(acrylic acid) interpolymer complex as an osmopolymer. AAPS PharmSciTech. 2011;12:132–140.
   PubMed Web of Science ®Google Scholar
• Li M, Si L, Pan H, et al. Excipients enhance intestinal absorption of ganciclovir by P-gp inhibition: assessed in vitro by everted gut sac and in situ by improved intestinal perfusion. Int J Pharm. 2011;403:37–45.
   PubMed Web of Science ®Google Scholar
• Zakeri-Milani P, Barzegar-Jalali M, Tajerzadeh H, et al. Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability: HPLC method development and validation. J Pharm Biom Anal. 2005;39:624–630.
   PubMed Web of Science ®Google Scholar
• Shah VP, Tsong Y, Sathe P, et al. In vitro dissolution profile comparison-statistics and analysis of the similarity factor, f2. Pharm Res. 1998;15:889–896.
   PubMed Web of Science ®Google Scholar
• Angeli F, Verdecchia P, Pascucci C, et al. Pharmacokinetic evaluation and clinical utility of azilsartan medoxomil for the treatment of hypertension. Expert Opin Drug Metab Toxicol. 2013;9:379–385.
   PubMed Web of Science ®Google Scholar
• Liu D, Yu S, Zhu Z, et al. Controlled delivery of carvedilol nanosuspension from osmotic pump capsule: in vitro and in vivo evaluation. Int J Pharm. 2014;475–496.
   PubMed Web of Science ®Google Scholar
• El-Zahaby SA, AbouGhaly MHH, Abdelbary GA, et al. Zero-order release and bioavailability enhancement of poorly water soluble Vinpocetine from self-nanoemulsifying osmotic pump tablet. Pharm Dev Technol. 2018;23:900–910.
   PubMed Web of Science ®Google Scholar
• Tang X, Tai LY, Yang XG, et al. In vitro and in vivo evaluation of gliclazide push-pull osmotic pump coated with aqueous colloidal polymer dispersions. Drug Dev Ind Pharm. 2013;39:67–76.
   PubMed Web of Science ®Google Scholar
• Fagerholm U, Johansson M, Lennernas H. Comparison between permeability coefficients in rat and human jejunum. Pharm Res.1996;13:1336–1342.
   PubMed Web of Science ®Google Scholar
• Qu CH, Tang R, Gao YL. Formulation design of different solubility drugs for osmotic pump tablet core. Chin J Hosp Pharm. 2005;25:1164–1165 (in Chinese).
   Google Scholar
• Verma RK, Arora S, Garg S. Osmotic pumps in drug delivery. Crit Rev Ther Drug Carrier Syst. 2004;21:477–520.
   PubMed Web of Science ®Google Scholar
• Shokri J, Ahmadi P, Rashidi P, et al. Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs. Eur J Pharm Biopharm. 2008;68:289–297.
   PubMed Web of Science ®Google Scholar
• Wen H, Li X, Li Y, et al. In vitro and in vivo evaluation of controlled-release matrix tablets of highly water-soluble drug applying different Mw polyethylene oxides (PEO) as retardants. Drug Dev Ind Pharm. 2018;44:544–552.
   PubMed Web of Science ®Google Scholar
• Kumaravelrajan R, Narayanan N, Suba V, et al. Simultaneous delivery of Nifedipine and Metoprolol tartarate using sandwiched osmotic pump tablet system. Int J Pharm. 2010;399:60–70.
   PubMed Web of Science ®Google Scholar
• Sotthivirat S, Haslam JL, Lee PI, et al. Release mechanisms of a sparingly water-soluble drug from controlled porosity-osmotic pump pellets using sulfobutylether-beta-cyclodextrin as both a solubilizing and osmotic agent. J Pharm Sci. 2009;98:1992–2000.
   PubMed Web of Science ®Google Scholar
• Aburub A, Risley DS, Mishra D. A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe. Int J Pharm. 2008;347:16–22.
   PubMed Web of Science ®Google Scholar
• Waterman KC, Macdonald BC, Roy MC. Extrudable core system: development of a single-layer osmotic controlled-release tablet. J Control Release. 2009;134:201–206.
   PubMed Web of Science ®Google Scholar
• Tian Z, Yu Q, Xie Y, et al. Controlling release of integral lipid nanoparticles based on osmotic pump technology. Pharm Res. 2016;33:1988–1997.
   PubMed Web of Science ®Google Scholar
• Patel A, Mehta T, Patel M, et al. Recent patent in controlled porosity osmotic pump. Recent Pat Drug Deliv Formul. 2013;7:66–72.
   PubMedGoogle Scholar
• Shokri J, Zarrintan MH, Ghanbarzadeh S, et al. The effect of pore-formers and plasticizers on the release kinetic of diltiazem hydrochloride from the controlled porosity osmotic pumps. Drug Res (Stuttg). 2013;63:414–419.
   PubMedGoogle Scholar
• Qin C, He W, Zhu C, et al. Controlled release of metformin hydrochloride and repaglinide from sandwiched osmotic pump tablet. Int J Pharm. 2014;466:276–285.
   PubMed Web of Science ®Google Scholar
• Lehto P, Kortejärvi H, Liimatainen A, et al. Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs. Eur J Pharm Biopharm. 2011;78:531–538.
   PubMed Web of Science ®Google Scholar